Hoth Therapeutics, Inc. (HOTH) - Dilution Analysis

10-Q filing | 19.1M shares outstanding

8-K filing: Hoth Therapeutics, Inc. sold 2,857,144 shares of common stock at $0.70 per share in a completed offering, with gross proceeds of approximately $2 million. ($2.0M proceeds)

10-K filing | 16.3M shares outstanding

10-Q filing | 15.5M shares outstanding

10-Q filing | 13.2M shares outstanding

10-Q filing | 12.7M shares outstanding

10-K filing | 13.2M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 4.9M shares outstanding

S-1 filing: Selling stockholders are offering on a resale basis an aggregate of 5,030,000 shares of common stock of Hoth Therapeutics, Inc. consisting of shares issuable upon exercise of warrants.

10-K filing | 4.4M shares outstanding

8-K filing: Hoth Therapeutics, Inc. entered into an inducement offer letter agreement with a warrant holder to exercise existing warrants for 2,500,000 shares at a reduced price of $1.6775 per share, in exchange for new warrants to purchase up to 3,750,000 shares at $1.50 per share, expecting gross proceeds of approximately $4.2 million. ($4.2M proceeds)

10-Q filing | 4.3M shares outstanding

8-K filing: Hoth Therapeutics, Inc. completed an offering of 549,275 shares of common stock and pre-funded warrants to purchase 550,725 shares, along with unregistered warrants to purchase one share of common stock for each share of common stock or pre-funded warrant purchased, resulting in gross proceeds of approximately $2.89 million. ($2.89M proceeds)

10-Q filing | 3.3M shares outstanding

S-3 filing: The company intends to offer and sell common stock, preferred stock, debt securities and warrants up to an aggregate amount of $25 million.

10-Q filing | 3.3M shares outstanding

10-K filing | 3.3M shares outstanding

S-3 filing: The filing relates to the registration of 4,600,000 shares of common stock for resale by selling shareholders, comprised of shares issued in a private placement and shares issuable upon exercise of warrants. The company will not receive any proceeds from the sale of shares by the selling shareholders, but will receive proceeds from any Warrants or Placement Agent Warrants exercised for cash.

8-K filing: Hoth Therapeutics, Inc. entered into a securities purchase agreement for a private placement of securities, including common stock, pre-funded warrants, and common stock warrants, for gross proceeds of approximately $10 million, with the closing expected on January 3, 2023. ($0.7M proceeds)

10-Q filing | 1.3M shares outstanding

8-K filing: Hoth Therapeutics, Inc. entered into a Subscription Agreement with an investor, issuing 2,000,000 shares of Series B Preferred Stock for $1,000. The company also filed a Certificate of Designation creating the Series B Preferred Stock. ($0.0M proceeds)

8-K filing: Stock split 1-for-25 | Outstanding: 31,034,205 → 1,241,368

10-Q filing | 31.0M shares outstanding

10-Q filing | 32.2M shares outstanding

10-K filing | 24.0M shares outstanding

10-Q filing | 24.0M shares outstanding

10-Q filing | 23.9M shares outstanding

10-Q filing | 23.9M shares outstanding

S-3 filing: S-3 filing for the resale of 15,569,621 shares of common stock by selling shareholders.

10-K filing | 22.8M shares outstanding

8-K filing: Hoth Therapeutics, Inc. entered into a securities purchase agreement to sell shares of common stock, warrants to purchase shares of common stock and pre-funded warrants to purchase shares of common stock in a private placement for gross proceeds of approximately $15 million. ($15.0M proceeds)

8-K filing: Hoth Therapeutics, Inc. entered into a Securities Purchase Agreement and sold 2,475,248 shares of common stock and warrants to purchase up to 1,237,624 shares in a private placement for $5 million gross proceeds, along with entering into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command. ($5.0M proceeds)

S-3 filing: This S-3 filing registers the resale of up to 3,712,872 shares of common stock by selling stockholders, including shares issuable upon exercise of warrants.

10-Q filing | 13.4M shares outstanding

10-Q filing | 13.4M shares outstanding

8-K filing: Hoth Therapeutics, Inc. entered into a Patent License Agreement with the George Washington University, granting the Company an exclusive license to intellectual property for a SARS-CoV-2 detection device, and in consideration, the Company agreed to issue GW ten year warrants to purchase up to 72,463 shares of the Company's common stock at an exercise price of $2.76 per share.

10-Q filing | 11.6M shares outstanding

S-1/A filing: This S-1/A filing relates to the registration of shares of common stock to be distributed as a dividend to AIkido Pharma Inc. stockholders and also discusses a previous public offering of common stock and warrants.

S-1 filing: Hoth Therapeutics, Inc. filed an S-1 form on 2020-04-03. The company is focused on developing new generation therapies for dermatological disorders.

8-K filing: Hoth Therapeutics, Inc. entered into an underwriting agreement for a public offering of 1,449,275 shares of common stock at $3.45 per share, expecting net proceeds of approximately $4 million. ($5.0M proceeds)

S-3 filing: This S-3 filing registers various types of securities, including common stock, preferred stock, debt securities, warrants and rights, for potential future offerings.

10-K filing | 10.1M shares outstanding